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Abstract
Background: The short, self-administered Gastroesophageal Reflux Disease (GERD) Symptom Frequency Questionnaire
(GSFQ) is a specific Quality of Life (QoL) instrument which measures the impact of GERD symptoms on QoL. This study
aims to map the specific scores in GSFQ into two generic instruments: SF-6D and EQ-5D-3 L, in order to obtain utility
estimates derived from the GERD condition.
Method: A national representative sample of GERD patients was selected, stratified by gender, age (< 45, ≥45 years)
and GERD severity (0-I, II-IV Savary-Miller score) for validation purposes. Age, gender, BMI, GERD diagnose, GERD severity,
associated comorbidities and risk factors were recorded. GSFQ, SF-6D, EQ-5D-3 L, and the HRQoL Visual Analogue Scale
(VAS) were answered by patients. Several mapping methods were estimated, regression using dummy variables, and
linear, quadratic and cubic regression using optimal factor scores. The use of a GERD aggregated summary severity
derived from the GSFQ was dimed the best predictor. Overall Mean Absolute Error (MAE), overall Mean Absolute
Percentage Error (MAPE) were used as goodness-of-fit (GOF) indexes to compare models.
Results: A total of 3405 patients were recruited by 490 clinicians. Mean age was 49 (±14.4) years and 49.8% were women.
Reported comorbidities were clustered in 6 antecedents and 15 concomitant pathologies. Aggregation of levels for the
frequency of symptoms items was found more suitable for estimation. Regression weights were found to follow a
monotonous progressive pattern. Overall MAE ranged from 0.092 to 0.094 for SF-6D utility prediction and from 0.
008 to 0.08 for EQ-5D-3 L, while MAPE values ranged from 27.9 to 29% for SF-6D and from 36.8 to 38.4% for
EQ-5D-3 L. Cubic regression GOF demonstrated a better fit.
Conclusions: It is possible to translate specific GSFQ scores assessing GERD condition into generic SF-6D and
EQ-5D-3 L utility values. Although regression using dummy variables is a suitable mapping procedure, other
alternative mapping methods convey better fit, in particular cubic regression.
Background
Gastroesophageal Reflux Disease (GERD) appears when
stomach contents flux back to the esophagus. It happens
when the valve located between the esophagus and the
stomach does not close properly. Most frequent disease
symptoms are acidity and acid reflux. Other less fre-
quent but associated symptoms are heartburn without
clear motive, panting, throat ache and cough, among
others [1, 2].
GERD can be classified into four severity levels, ranging
from the appearance of edema and erythema, causing
some degree of esophagus erosion, up to esophageal ulcers
or Barret’s esophagus. Consumption of alcohol or carbon-
ated drinks, obesity and smoking are known to be GERD
risk factors [3].
According to the DIGEST international study, ap-
proximately 7.7% of the population suffers from GERD
[4]. Attending to the current consensual definition:
“GERD should be used to include all individuals who are
* Correspondence: Miguel.ruiz@uam.es
1Faculty of Psychology, Universidad Autónoma de Madrid, C/ Ivan Pavlov 6,
28049 Madrid, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Monroy et al. Health and Quality of Life Outcomes  (2018) 16:177 
https://doi.org/10.1186/s12955-018-1003-y
exposed to the risk of physical complications from gastro-
esophageal reflux, or who experience clinically significant
impairment of health related well-being (quality of life)
due to reflux related symptoms, after adequate reassur-
ance of the benign nature of their symptoms” [5]. Further-
more, it is commonly accepted that self-reporting is one
of the main sources of diagnosis [6] and patients should
report experiencing symptoms at least twice a week [2, 7]
for a diagnosis of GERD.
It is important to remark that the impairments caused
by GERD symptoms are highly variable and may affect
quality of life even when there are no endoscopic find-
ings [2]. Patients tend to adopt eating behaviors in order
to prevent or attenuate their clinical situation. The
Agency for Healthcare Research and QALY reports that
the more frequent treatments are antacids (neutralizing
stomach acids) and type 2 histamine receptor antago-
nists (H2RA) or proton pump inhibitors (PPI), both re-
ducing the production of stomach acid [8, 9]. The
impacts of GERD symptoms on patients’ health-related
quality of life (HRQoL) is usually ascertained by means
of patient-reported-outcomes measurements (PROMs)
such as the Gastrointestinal Short Form Questionnaire
(GSF-Q) [10].
HRQoL measures are particularly important for GERD
sufferers given their diagnostic capabilities, while they
also reveal important issues to health service providers
for several reasons. First, HRQoL has been shown to
have a direct relation with mortality, hospitalization and
consumption of clinical resources. Second, it has been
shown to have a low to moderate relation with other
disease-specific indicators, hence contributing comple-
mentary information for assessing clinical impairment
[11]. Presently, HRQoL has been identified as a clinical
target in itself, both in patients with limited life expect-
ancy and for therapies directed towards disease coping
or symptom accommodation, as much as for biological
improvement (as is the case for most chronic diseases).
Preference-based measures (PBMs) play a central role in
these evaluations. They allow patients to describe the
impact of ill health and have an associated “utility” score
for each health-state description. These utility scores can
then be used to calculate quality-adjusted life-years
(QALYs), which is an outcome metric used in many eco-
nomic evaluations of potential health benefits [12].
In the past, clinical studies did not always include a
PBM. Often they included one or more of the many
PROMs that are not full PBMs because they do not have
an associated, preference-based scoring system. On the
other hand, PROMs have proved to be very sensitive to
variations in patient health conditions, and this is one of
the reasons for their extended use in clinical studies.
Furthermore, when a major research need is to compare
result with those of other pathologies or comorbidities,
it will not be possible to use disease-specific PROMs,
and generic HRQoL instruments should be preferred.
Most popular generic instruments (like SF-6D, EQ-5D
and HUI3), offer the possibility of computing the utility
score associated to each health condition (as captured
by the instrument attribute profile), reflecting the popu-
lation preference towards each health state in a situation
of uncertainty. This peculiarity allows using them in
computing QALYs and in health economics in general.
It is usually the case that a disease-specific PROM in-
strument will be preferred in research about a particular
disorder and when the use of generic instruments has
been avoided because they do not capture properly the
different levels of disease symptomatology on patients’
HRQoL. Also, because there is evidence suggesting that
generic measurements might have poor sensitivity to
change in some health conditions, such as GERD or
others non-threatening illnesses, or are incapable of dis-
criminating well between patients using different drugs
to treat their health problems [13, 14]. In such cases, the
usual strategy is to map the specific measurements into
a generic instrument allowing further comparison with
other studies in which the specific instruments may not
be pertinent or are otherwise unavailable (e.g., retro-
spective databases) [15, 16].
Aligned with such an approach, since 2008, NICE’s pre-
ferred measure of health-related quality of life in adults
has been EQ-5D, to derive utilities set values for health
economic evaluations (see Guide to the methods of tech-
nology appraisal 2013, at https://www.nice.org.uk/process/
pmg9/chapter/foreword.
The aim of the present study was to obtain the map-
ping algorithms needed for translating the specific
HRQoL measure obtained by the GSF-Q into two of the
most popular preference-based generic instruments, the
SF-6D and the EQ-5D-3 L. As a secondary benefit, we
will be able to assess which one of the generic instru-
ments is more suitable for capturing HRQoL deterior-
ation due to GERD conditions.
Methods
Study design
The present study is a secondary analysis carried out
using the data gathered for the cultural validation of the
GSF-Q into Spanish [17]. The original study was devel-
oped to ensure adequate estimation of psychometric
properties, and was designed as an observational study
that would provide a rich data set, not only for instru-
ment validation but particularly for mapping studies, be-
yond what could be obtained in controlled clinical trials.
This was a cross-sectional, single time point assessment de-
sign. The original sample design was thought to ensure rep-
resentativeness of three strata: gender, age (< 45, ≥45 years)
and symptom severity (Savary-Miller: 0-I, ≥II). Patients
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were selected at random by demand of attention and cover-
ing each sample stratum. Scales were administered in a sin-
gle visit. Patients were over 18 years of age, able to read
Spanish, and signed an informed consent form. The Ethics
Committee of one of the participating centers in the valid-
ation study was responsible for approving the study design.
Clinicians were recruited at random and proportionally on
the geographical extension and service demand in the
Spanish Autonomous Communities. The study recruited
the participation of 510 gastroenterologists, and they were
requested to provide 4 to 8 subjects each. Additional data
on the study design may be found elsewhere [17].
Participants
The final sample was composed by 3405 patients, from
whom 2251 completed all the questionnaires, sociode-
mographic and clinical data. Half of the participants
were women (49.8%), 63.9% were obese, 40.1% smokers,
42.8% consumed alcohol, and 46.5% consumed carbon-
ated beverages. GERD was diagnosed in 80% of cases,
46.3% were under IBP treatment, 16.5% used H2RA, and
25.3% used antacids. It should be mentioned that 48.4%
were on treatment for at least one other comorbidity
(Table 1). All patients had signed informed consent
forms, and the Helsinki declaration guidelines were met.
Instruments
Three questionnaires were used to measure HRQoL,
the 2 most popular generic ones and a GERD specific
instrument.
The Gastrointestinal Short Form Questionnaire (GSF-Q)
[6, 7], was used to measure GERD symptom impact on
HRQoL. The questionnaire is composed of six items, plus
2 filter items. The first four gauge the impact of GERD
symptoms during the most recent week (upper abdomen
pain, breastbone pain, limited eating, heartburn) using a
5-point Likert scale (0 =Never, 4 = All of the time). The
last two inquire about the number of days per week with
daytime or nighttime disturbances (0–7 days). The total
score is obtained by adding up individual item scores, and
it is customary to rescale it into a 0–100 severity scale. A
higher score represents a higher impact on HRQoL and
scores are usually interpreted by comparison with popula-
tion norms [17].
EuroQol-5 Dimension-3 Levels (EQ-5D-3L) [18, 19] is
a generic, preference-based HRQoL instrument. It gathers
the level of deterioration for 5 attributes: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression;
using 3-level items (1 = none, 2 = some problems, 3 = a lot
of problems). Each combination of levels creates a health
profile, with a total of 243 possible health states, although
not all of them are equally likely. Profile [11111] corre-
sponds to perfect health and profile [33333] represents the
worse possible health state. Based on population preference
ranking, health states are translated to a social utility value
using a multi-attribute utility function (MAUF). Different
MAUFs are used for different countries, mainly using
estimates based on Time Trade-Off (TTO) and Visual
Analogue Scale (VAS) methods [20]. The basic form of the
EQ-5D-3 L MAUF is:
ui ¼ 1− q þ
Xj¼5
j¼1
Xk¼3
k¼1
bjkDijk þ bN3N3i
 !
Where the utility/preference value for health state i
(ui) is obtained by subtracting from 1 the health state
disutility (ui). Disutility is obtained by weighting (bjk) the
Table 1 Sample sociodemographic and clinical descriptors
Variable Level Frequency Percent
Age (decades) 18–30 147 6.5
31–40 392 17.4
41–50 510 22.7
51–60 529 23.5
61–70 431 19.1
71–80 187 8.3
> 80 55 2.4
Gender Male 1131 50.2
Female 1120 49.8
Smoking Yes 903 40.1
No 1348 59.9
Alcohol Yes 963 42.8
No 1288 57.2
antiH2 Yes 348 15.5
No 1903 84.5
Treated for comorbidities Yes 1161 51.6
No 1090 48.4
GERD Level 0 396 17.6
1 521 23.1
2 583 25.9
3 220 9.8
4 102 4.5
Unknown 429 19.1
Body Mass Index Infra-weight 17 .8
Normal 796 35.4
Over-weight 1438 63.9
Carbonated Drinks Yes 1047 46.5
No 1204 53.5
IBP Yes 965 42.9
No 1286 57.1
Antacid Yes 556 24.7
No 1695 75.3
Monroy et al. Health and Quality of Life Outcomes  (2018) 16:177 Page 3 of 11
deterioration level k attained in dimension Dj, plus an
interaction term (N3i), which adds a constant bN3 when
any of the dimensions reaches its maximum deterior-
ation level, plus a constant (q). It should be noted that
bj1 = 0 for the first level of any dimension (k = 1), which
represents no deterioration in that dimension [21].
The Medical Outcomes Survey Sort Form-6 Dimension
(SF-6D) [22, 23] is a generic, preference-based HRQoL
instrument derived from the 36-item MOS SF-36 [24]. It
gathers the level of deterioration for 6 dimensions: phys-
ical functioning, role limitations, social functioning, pain,
mental health, and vitality; using a recoding of 11 specific
items into 4 to 6 levels. A total of 18,000 health profiles
are possible, with the profile [111111] corresponding to
perfect health and [645655] representing the worse pos-
sible health state. Different MAUFs have been estimated
for deriving preference utilities in different countries, with
the peculiarity that no severity (interaction) constant is
used. As in the previous case, a value of 0 is assigned to
the first level for each dimension/attribute.
Statistical analyses
The first step consisted in checking the unidimensional-
ity of GSF-Q items and, if met, deriving an overall sever-
ity index due to GERD condition. This severity index
will be used to short generic health states (EQ-5D-3 L or
SF-6D) when their corresponding profiles differ only in
the permutation of one severity level, e.g.: [11112] vs.
[11121]. A first approach was to estimate a unidimen-
sional latent variable model assuming the latent variable
to be continuous and items/indicators to be ordinal
while using the WLSMV estimation method. A second
approach was to decompose each k-categories item into
a series of k dummy variables (0 = No, 1 = Yes) and cod-
ing lower level dummy categories as fulfilled (1) when a
particular item-level was reached. A Partial Credit model
[25] (an extension of the Rasch model) using ML estima-
tion was obtained. In this way, estimated category thresh-
olds could be compared across items and monotonic
distribution of item step thresholds could be checked.
Observed EQ-5D and SF-6D utility mean scores were
compared using standard t-test and using bootstrap esti-
mates in order to avoid the influence of skewness and ex-
treme utility values.
Once a summary GERD-specific severity index was
obtained, this index was mapped onto each of two utility
values (separately), and several models were tested (see
below) in order to predict the utility value associated to
each GERD severity condition.
Disutility values (di = 1-ui) were modeled, instead of
utility values, for several reasons. First, the data-mass
usually concentrates around more lenient health states,
and low disutilities will fall closer to the axis origin. Sec-
ond, it is always possible to estimate a model without
the intercept term, anchoring 0 value disutilities (perfect
health) at the 0 GERD severity value. Since GERD is not
necessarily a disabling condition, and in order to attenuate
the impact of possible comorbidities in the disutility value
for each individual, disutilities were aggregated, using the
mean value, by GERD severity, before modelling.
The following regression models estimated linear, quad-
ratic and cubic trends, using density function values, and
Tobit and Probit, using cumulative distribution values.
The following covariates were tested for inclusion: Age
(decades), BMI (low, normal and overweight), GERD diag-
nosis (Yes), smoking, alcohol consumption, carbonated
drinks consumption, IBP treatment, H2RA treatment, ant-
acid treatment, and treatment for comorbidities. In order
to anchor the best possible health states in both in-
struments, the GERD severity factor scores were
rescaled into the range 0–1, and regression models
were fit through the origin.
Along with the statistical significance of regression
coefficients, model goodness-of-fit (GOF) was assessed
using R2, mean absolute error (MAE) and mean abso-
lute percentage error (MAPE). MAE and MAPE were
computed overall and by quintile group based on sever-
ity scores to assess local GOF at the different levels of
severity. Bootstrap estimates for model coefficient
standard errors were also obtained to avoid the
influence of outlier observations in the assessment of par-
ameter significance levels. General internationally-accepted
guidelines proposed for instrument mapping were
followed [13].
All analyses were conducted using the SPSS for Windows
statistical software, version 22.0 and Mplus 7.
Results
GSF-Q scores ranged between 0 and 30 with a mean
value of 10.54 (SD = 5.94). GERD Severity summary
scores (factor scores) ranged between − 1.40 and 1.88
with a mean value of 0 (SD = 0.636) with a symmetric
distribution (Skewness = 0.021, SE = 0.052).
At the individual level, SF-6D mean utility scores (MSF =
0.656, SDSF = 0.207) were significantly lower than
EQ-5D-3 L scores (MEQ = 0.744, SDEQ = 0.206), both under
asymptotic assumptions (t = − 27.54, p < 0.001) and using
10.000 bootstrap samples: Difference 95% CI = (− 0.093,
− 0.081), suggesting that slightly higher utilities were
obtained with the EQ-5D. As expected, both utility
scores showed a marked negative skewness, SF-6D:
SkewnessSF = − 0.784, SESF = 0.052; EQ-5D-3 L: Skew-
nessEQ = − 1.049, SEEQ = 0.052, with a high correlation
between them (r = 0.733, p < 0.001).
The first eigenvalue of the correlation matrix was λ =
3.55 and all further eigenvalues were below 1. The
confirmatory factor analysis for the 1-dimension solu-
tion (assuming variables to be ordinal) attained good
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GOF indexes with CFI = 0.951 and TLI = 0.918. Figure 1
shows the cumulative distribution for rescaled factor
scores, exhibiting a smooth ogive distribution with no evi-
dent changes in curvature. This figure may be used as nor-
mative data to obtain percentiles from severity scores.
Figure 2 represents the response category thresholds for
each item with respect to the latent normal severity score.
In this figure, severity scores are expressed in standard de-
viations from the mean latent severity of 0 and, for each
GSF-Q item, partial credit thresholds for each step rating
Fig. 2 GSF-Q item thresholds assuming unidimensionality (Partial Credit Model)
Fig. 1 GSF-Q severity score cumulative distribution
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response are plotted, showing a rather even spread and
separation of rating categories for the first four items, and
a displacement of the category thresholds above the mean
severity for the last two items of daytime and nighttime
limitations. This later result is in accordance with the
smaller weight received by the two last items in comput-
ing the factor score.
The resulting equation needed for computing re-scaled
estimated factor scores from observed GSF-Q items scores
may be expressed as follows:
f^ i ¼ ð0:183x1i þ 0:204x2i þ 0:100x3i þ 0:174x4i
þ0:047x5i þ 0:044x6i þ 1:4025Þ  0:30479
Where x1 to x4 are the scores in the first 4 GSF-Q
items (0 = Never, 4 = Always), x5 is the number of days
with disability, x6 is the number of nights with GERD
problems, and 1.4025 and 0.30479 are scaling constants
moving the factor scores into the 0–1 range.
EQ-5D-3 L showed to be particularly less sensitive to
GERD severity. Only 78 (32%) of the 243 possible
EQ-5D-3 L profiles were observed and 17 (7%) of them
gathered more than 90% of patients. Table 2 shows the
most frequent EQ-5D-3 L profiles observed in our sam-
ple. In the case for SF-6D utility scores, 975 (5.4%) out
of the 18,000 possible health states were observed, 35
(0.2%) profiles presented a prevalence above 5/1000,
gathering only 25.5% of cases.
The best fitting model for mapping GSF-Q into SF-6D
disutilities was a cubic model including variables GERD
severity (linear, quadratic and cubic), age (in decades),
gender, BMI group (infra, normal, and over-weight), and
being treated for comorbidities (see Table 3). The model
GOF was good (R2 = 0.888), with MAE = 0.092 and
MAPE = 27.9% (Table 4) Fig. 3.
The best fitting model form mapping GSF-Q onto
EQ-5D-3 L disutilities was the cubic model including
GERD severity (linear, quadratic and cubic), age (in de-
cades), gender, and being treated for comorbidities. BMI
group was not significant and the following GOF statistics
were obtained: R2 = 0.831, MAE = 0.086 and MAPE =
37.0%.
Discussion
Specific HRQoL instruments are the preferred choice for
measuring patient perceptions on their health condition
Fig. 3 SF-6D: (up) and EQ-5D-3 L (down) observed (blue) and predicted (green) utility values vs. GERD severity for the linear (left), quadratic
(center) and cubic (right) models
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Table 2 Most prevalent EQ-5D-3 L and SF-6D health
state profiles, associated utilities, and frequencies
(cases, percentages and cumulative percentages; partial
listing)
Profile Utility Freq. Percent Cum. %
EQ-5D
11111 1.00 566 25.1 25.1
11121 .79 376 16.7 41.8
11122 .74 294 13.1 54.9
11222 .68 166 7.4 62.3
21222 .59 118 5.2 67.5
11112 .80 107 4.8 72.3
11221 .74 99 4.4 76.7
22222 .49 52 2.3 79.0
21221 .65 50 2.2 81.2
21121 .70 36 1.6 82.8
21122 .65 31 1.4 84.2
11223 .42 30 1.3 85.5
22232 .22 30 1.3 86.9
22221 .54 22 1.0 87.8
11232 .41 17 .8 88.6
21232 .32 17 .8 89.3
11233 .36 16 .7 90.0
11211 .79 15 .7 90.7
11123 .48 14 .6 91.3
21233 .27 12 .5 91.9
22233 .17 12 .5 92.4
11113 .54 10 .4 92.8
21111 .76 10 .4 93.3
21223 .33 10 .4 93.7
22223 .23 10 .4 94.2
11212 .74 8 .4 94.5
12222 .58 7 .3 94.8
21112 .71 7 .3 95.2
21131 .43 7 .3 95.5
21231 .37 7 .3 95.8
11231 .46 6 .3 96.0
22332 .17 6 .3 96.3
12221 .63 5 .2 96.5
11131 .52 4 .2 96.7
12121 .69 4 .2 96.9
12233 .26 4 .2 97.1
21132 .38 4 .2 97.2
12223 .32 3 .1 97.4
21211 .71 3 .1 97.5
Table 2 Most prevalent EQ-5D-3 L and SF-6D health
state profiles, associated utilities, and frequencies
(cases, percentages and cumulative percentages; partial
listing) (Continued)
Profile Utility Freq. Percent Cum. %
SF-6D
111222 .86 52 2.3 2.3
111112 .94 30 1.3 3.6
111223 .86 30 1.3 5.0
111122 .88 29 1.3 6.3
111123 .88 22 1.0 7.2
111322 .84 19 .8 8.1
111111 1.00 18 .8 8.9
111212 .92 18 .8 9.7
111224 .79 18 .8 10.5
211224 .78 17 .8 11.2
212324 .73 17 .8 12.0
112324 .74 16 .7 12.7
211222 .84 16 .7 13.4
111323 .84 15 .7 14.1
211323 .83 15 .7 14.7
111225 .76 14 .6 15.4
111324 .78 14 .6 16.0
113424 .55 14 .6 16.6
211324 .76 14 .6 17.2
212323 .79 14 .6 17.9
212325 .69 14 .6 18.5
312323 .77 14 .6 19.1
111121 .93 13 .6 19.7
112322 .80 13 .6 20.3
112323 .80 13 .6 20.8
113324 .72 12 .5 21.4
211223 .84 12 .5 21.9
212322 .79 11 .5 22.4
111221 .92 10 .4 22.8
111325 .74 10 .4 23.3
112222 .82 10 .4 23.7
211322 .83 10 .4 24.2
212224 .74 10 .4 24.6
311324 .75 10 .4 25.1
312324 .71 10 .4 25.5
111124 .81 9 .4 25.9
112122 .84 9 .4 26.3
113323 .78 9 .4 26.7
212223 .81 9 .4 27.1
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because of their high sensitivity to changes due to dis-
ease management and treatment suitability. However,
mapping specific HRQoL into generic utility scores can
present methodological problems. Albeit the good psycho-
metric properties of instruments like GSF-Q for measuring
the impact of GERD on patients’ daily lives [10, 17, 26],
GERD is a relatively mild health disabling disease, as com-
pared to other possible health states measured by generic
instruments. Besides, it is difficult to instruct patients to
restrict their thinking to only one specific disease-re-
lated disability, isolating their judgments from other
comorbidities that might be present, or from the im-
pact of normal disabilities associated with to aging,
when responding to generic instruments. The final re-
sult is that generic instruments might capture the
effects of other disabilities and limitations which are
not be directly related to the specific disease being
mapped.
One possible strategy for avoiding these problems
would be to design a preference-choice experiment with
the health conditions vignettes derived from the specific
instrument [27]. Unfortunately, it could be expected that
marginal disutilities could be oversized if other, very
severe health conditions are included as anchoring. An-
other possibility could be to describe specific health con-
ditions only by the set of generic health profiles that are
Table 3 Estimated model coefficients
Model Predictor SF-6D disutility EQ-5D-3 L disutility
B SE Beta Sig B SE Beta Sig
Linear GSF-Q severity .481 .014 .592 <.001 .441 .011 .688 <.001
Age (decade) .012 .002 .124 <.001 .010 .002 .132 <.001
Gender (Female) .041 .005 .077 <.001 .027 .005 .064 <.001
BMI (Grouped) .019 .006 .080 <.001 – – – ns
Comorbidities (Treated) .043 .003 .132 <.001 .034 .006 .082 <.001
Quadratic GSF-Q severity .241 .044 .297 <.001 .195 .042 .304 <.001
GSF-Q severity (square) .291 .051 .214 <.001 .309 .049 .288 <.001
Age (decade) .013 .002 .138 <.001 .013 .002 .171 <.001
Gender (Female) .045 .005 .084 <.001 .032 .005 .076 <.001
BMI (Grouped) .031 .004 .217 <.001 .009 .004 .078 .020
Comorbidities (Treated) .040 .006 .075 <.001 .031 .006 .074 <.001
Cubic GSF-Q severity .610 .091 .751 <.001 .527 .170 .485 <.001
GSF-Q severity (square) −.822 .245 −.605 .001 −.665 .207 −.620 .001
GSF-Q severity (cube) .891 .192 .444 <.001 .768 .068 .823 <.001
Age (decade) .012 .002 .128 <.001 .013 .002 .167 <.001
Gender (Female) .043 .005 .080 <.001 .030 .005 .071 <.001
BMI (Grouped) .041 .006 .078 <.001 – – – ns
Comorbidities (Treated) .023 .004 .163 <.001 .032 .006 .077 <.001
ns not significant
Table 4 Estimated model goodness of fit statistics
Model Overall MAE MAPE (%)
R2 Adj. R2 Overall Q1 Q2 Q3 Q4 Q5 Overall Q1 Q2 Q3 Q4 Q5
SF-6D
Linear .885 .885 .094 .067 .076 .078 .123 .127 29.0 39.0 26.1 23.0 30.8 26.2
Quadratic .887 .886 .093 .065 .075 .069 .122 .126 28.1 33.4 27.2 23.6 31.3 25.2
Cubic .888 .887 .092 .065 .075 .069 .120 .125 27.9 33.6 26.0 23.3 31.4 25.2
EQ-5D-3 L
Linear .827 .826 .008 .065 .076 .073 .101 .124 38.4 62.3 37.0 28.7 32.6 32.0
Quadratic .830 .829 .086 .065 .076 .069 .099 .121 36.8 52.2 40.0 29.0 32.8 30.2
Cubic .831 .831 .086 .065 .076 .076 .098 .119 37.0 33.6 38.2 28.9 33.1 29.8
MAE Mean Absolute Error, MAPE Mean absolute percentage Error, Q1-Q5 quintile groups
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prevalent and meaningful in the particular disease, and
only mapping those conditions. This approach could be
used when observed distributions like the one obtained
for the EQ-5D-3 L are found (see Table 2), and a reduced
number of health states gather the majority of patients.
But, very large samples would need to be used, if the in-
tent is to obtain representative results, and it could be
cumbersome when the number of possible health states is
very large, as has happened with the SF-6D (Table 2).
In the time being, directly mapping specific health states
onto generic utility values seems to remain the best op-
tion, and special care should be taken, by aggregating gen-
eric utility values over specific severity scores, in order to
smooth out the impact of non-specific effects on the map-
ping estimates. The present paper reports the first study
mapping GSF-Q onto two of the most widely used generic
HRQoL instruments. In fact, our study could be consid-
ered to have high ecological validity due to the large sam-
ple used and its ample representativeness.
In our study, GERD was found to be a quite lenient
pathology, with mean utility values of 0.656 (SF-6D) and
0.744 (EQ-5D-3 L). In fact, the most prevalent health-at-
tribute level reported was the first (no deterioration), in
both generic instruments, except for the attributes/di-
mensions of pain and Mental Health (see Table 5). Even
the scaling of the response levels of one’s own GSF-Q
suggests that the third response level (L2 in Fig. 2) had
been selected by patients in order to be located above
the mean in the latent (error-free) severity score for all
items, except for the number of days with problems.
These results are in agreement with regular GERD diag-
nosis, which states that stomach problems should be
present more than 2 days a week in order to be consist-
ent with GERD [7].
Obtained SF-6D utility scores were shown to be more
sensitive to GERD-severity than those obtained from
EQ-5D-3 L.The distribution of the former was more spread
out, with less likelihood of ceiling effects, and did not ex-
hibit a gap between perfect health, u(11111) = 1, and the
following larger value, as it was the case with the later,
u(11121) = 0.79. The observed cumulative distribution
function of SF-6D disutility scores was more uniform;
the distribution function of EQ-5D-3 L disutilities
was steeper (especially in the milder health states)
and the distributions did not cross over within their
ranges.
GSF-Q scores showed good unidimensional behavior
which allowed summarization of GERD-related severity in
a single score using factor analysis weights. Unidimension-
ality analyses endorsed the possibility of summarizing the
different GERD symptoms in an aggregated overall score,
also obtaining an adequate scaling of response levels. In
our case, this strategy should be preferred against one
using item-response dummy coding in the regression
models, since it avoids deciding how to aggregate item
response levels [28] and minimizes the possible impact
of covariates in particular response levels.
For each of the generic instruments, the best-fitting
model was selected. In both cases, the model including
GSF-Q severity (observed, squared and cubed), age, gen-
der, and being treated for comorbidities attained the best
fit, and the SF-6D model additionally included BMI. The
sign of the regression coefficients were in accordance with
predicting a higher disutility as GSF-Q severity scores in-
crease. The inclusion of significant covariates by all models
suggests that the loss in HRQoL may be influenced not
only by GERD symptoms but also by personal comorbidi-
ties present. This is to say that GERD symptoms may be
not very prominent when assessing HRQoL using a gen-
eric instrument if other health conditions might be
present, such as aging, being treated for comorbidities and
overweight.
R2 values were within the range 0.885–0.888 for model
SF-6D, and within 0.827–0.831 for model EQ-5D-3 L.
Overall MAPE = 27.9% for predicting SF-6D and MAPE =
37.0% for predicting EQ-5D-3 L when using predictions
derived from the cubic model. Computing predicted
SF-6D disutility MAPE by GSF-Q severity quintile groups,
MAPE ranged between 33.6% for Q1 and 23.3% for Q3
while for predicted EQ-5D-3 L disutility, MAPE ranged
between 33.6% for Q1 and 28.9% for Q3 (see Table 4). As
expected, the error magnitude was smaller near the
Table 5 Percentage of responses by dimension level for each dimension/attribute of the EQ-5D-3 L and SF-6D generic instruments
Dimension EQ-5D-3 L Dimension SF-6D
Dimension Level Dimension Level
1 2 3 1 2 3 4 5 6
Mobility 78.4% 21.2% 0.4% Physical Function 35.6% 27.8% 22.2% 2.5%. 10.5% 1.4%
Self-care 91.5% 8.1% 0.4% Role Limitation 54.9% 12.2% 18.3% 19.6% * *
Daily activities 66.0% 32.7% 1.3% Social Function 36.4% 28.7% 27.1% 7.0% 0.8% *
Pain 32.8% 59.9% 7.3% Pain 12.3% 19.5% 34.8% 18.7% 13.2% 1.4%
Anxiety/Depression 54.6% 39.1% 6.3% Mental Health 10.8% 61.8% 17.6% 7.8% 2% *
Vitality 5.3% 19.3% 22.8% 28.9% 16.9% 6.8%
* Unused dimension level
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location of the centroid; while it was particularly high
when predicting EQ-5D-3 L disutilities using the linear
model (up to 62.3% in Q1).
Some additional covariates, like smoking and drinking
carbonated beverages or alcohol, approached statistical
significance, but all models were kept as parsimonious as
possible, and only statically-significant predictors were
included (p < 0.05). Bootstrap estimates were generated,
based on 1000 samples with replacement, obtaining par-
ameter estimate bias smaller than |0.002| and significance
levelsp^≤0:002.
Mapping disease-specific instruments onto generic
health related measures is a common methodological
strategy due to the high sensitivity of specific instru-
ments and the wide generalizability of generic measures.
Mapping the GERD-specific GSF-Q scores onto generic
utilities (SF-6D and EQ-5D-3 L) was shown to be pos-
sible, attaining adequate goodness-of-fit values. In both
cases, the best-fitting model was the more complex one;
the model based on GSF-Q severity, raised to the cubic
power, and including generic covariates: age, gender,
BMI and treatment for comorbidities. However, the
model for predicting EQ-5D-3 L disutilities did not in-
clude BMI as a statistically significant covariate.
The use of cubic prediction models needs special care,
since small variations in the cubed predictors can entail
excessively large predicted values, including those for
predictors out of the range of the observed data used for
prediction, that can produce unreasonable predictions.
In our case this prevention is needless, given that all
GERD severity values are scaled within the 0–1 range
(any value will have to be inside the range of values used
for estimation), and possible covariate values are limited
to the observed repertoire.
In our study, we found that utility values associated with
GERD-specific conditions were rather high, suggesting that
this disease is not very disabling (in general). Nevertheless,
patients with utility values as low as SF-6D = − 0.3150 and
EQ-5D-3 L = − 0.0757 were observed, although they were
not always associated with the worst GSF-Q severity scores.
Given the reduced number of prevalent health states
obtained for the generic instruments (especially for
EQ-5D-3 L) the question arises whether some charac-
teristic or “natural” disease-related health states could
be identified for each generic instrument, discarding
other comorbidity-influenced health states. From a
nosological point of view, it looks quite tempting to
think that GERD would not entail a high deterior-
ation in mobility, but it could be the case that
bed-ridden people might very likely develop GERD.
One possible way to minimize the impact of comor-
bidities, when measuring specific health conditions
with a generic instrument, would be to use a set of
instructions demanding that the patient assess his or
her overall health condition while thinking only of his
or her specific disease.
Limitations
The present study has been carried out with a Spanish
population, and we cannot ensure that other cultural or
eating habits would not distort our results.
Conclusions
In the present study two methods are presented allowing
the mapping of specific GERD-severity scores obtained
by use of the GSF-Q, onto generic HRQoL values, as
measured by the SF-36 and EQ-5D-3 L instruments. In
both cases, the cubic model attains best adjustment.
Mapping is an approach that enables utilities to be
predicted for the calculation of quality-adjusted life-
years when no preference-based information has been
elicited what will allow to elaborate health economic
evaluations in a simpler way, since it is not necessary to
have data of no preference-based instruments. The re-
sults of this study will allow to carry out economic evalua-
tions in the world of gastroesophageal reflux disease which
will help in the future when it is necessary to make deci-
sions with new alternatives that arrive at the market.
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